Opus Genetics (NASDAQ: IRD) posts J.P. Morgan conference deck online

Rhea-AI Filing Summary

Opus Genetics, Inc. is highlighting its business at the 44th Annual J.P. Morgan Healthcare Conference, where management will deliver a corporate presentation on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the talk will be available through the company’s investor relations website, allowing investors to listen remotely. The associated January 2026 corporate presentation is provided as Exhibit 99.1 and is also posted in the “Overview” section of the company’s investor site.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000122862700012286272026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-34079	11-3516358
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Davis Drive Durham, NC		27713
(Address of principal executive offices)		(Zip Code)

(984) 884-6030

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	IRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

As previously announced, management of Opus Genetics, Inc., a Delaware corporation (the “Company”), will be delivering a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the presentation will be accessible through the investor relations section of the Company’s website. The presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company has also made the presentation available to investors on the “Overview” section of the Company’s website at https://ir.opusgtx.com.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	January 2026 Corporate Presentation.
104.1	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OPUS GENETICS, INC.
Date: January 12, 2026	By:	/s/ Dr. George Magrath
	Name:	Dr. George Magrath
	Title:	Chief Executive Officer

FAQ

What did Opus Genetics (IRD) announce in this 8-K?

Opus Genetics announced that management will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference, with the January 2026 slide deck available to investors.

When will Opus Genetics (IRD) present at the J.P. Morgan Healthcare Conference?

Opus Genetics’ management is scheduled to present on January 15, 2026 at 8:15 a.m. Pacific Time at the 44th Annual J.P. Morgan Healthcare Conference.

How can investors access Opus Genetics’ J.P. Morgan conference presentation?

Investors can access a live webcast of the presentation through the investor relations section of Opus Genetics’ website and view the slide deck posted in the site’s “Overview” section.

What is Exhibit 99.1 in Opus Genetics’ latest report?

Exhibit 99.1 is Opus Genetics’ January 2026 Corporate Presentation, which accompanies the company’s appearance at the J.P. Morgan Healthcare Conference.

Is the Opus Genetics (IRD) conference presentation considered filed with the SEC?

The company states that the information related to the presentation, including Exhibit 99.1, is furnished and not deemed filed for purposes of the Securities Exchange Act of 1934.